Merryman, R., Keudell, G. V., Redd, R., Walker, H., Mahns, J., Normilus, S., Sagedahl, S., Vogiatzi, I., Zhang, M., Sumpena, E., Chuan, W., Ahn, I., Bessnow, A., Brown, J., Crombie, J., Davids, M. S., Fisher, D., Hahn, C., Jacobsen, E., Jacobson, C., Kim, A., LaCasce, A., Odejide, O., Parry, E., Qualls, D., Ryan, C., Sekar, A., Cherng, H., Murakami, M., Armand, P., Brody, J. (2025). Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial. Blood. https://doi.org/10.1182/blood-2025-3602